Global Cell Culture Market Overview:
According to SPER Market Research, the cell culture market estimated to reach USD 59.8 billion by 2030 with a CAGR of 11.2%. Rising prevalence of infectious diseases and growing awareness for health has influenced the adoption of cell culture for vaccines, monoclonal antibodies and personalized medicine.
Impact of COVID-19 on the Cell Culture Market
COVID-19 pandemic has prompted the development of vaccines for immunization. Cell culture has played an important role in the manufacturing of the vaccines against SARS-CoV-2. Cell culture provides safe and continuous production of substrates for viral vaccines. This development has impacted to the growth of the cell culture market.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2019-2030 |
| Base year considered | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | By Product, By Application, By End User |
| Geographies covered | North America, Europe, APAC, Latin America and the Middle East & Africa |
| Companies Covered | Adolf Kühner AG, Agilent Technologies, Inc., ANGUS Chemical Company, Becton, Dickinson and Company, Biospherix Ltd., Caisson Laboratories Inc., Cellexus, Corning Incorporated, Danaher Corporation, Eppendorf AG, FUJIFILM Irvine Scientific, Inc., Getinge AB, HiMedia Laboratories, InvivoGen, Lonza Group AG, Meissner Filtration Products Inc., Merck KGaA, Miltenyi Biotec, Pan-Biotech GmbH, PromoCell GmbH, Sartorius AG, SeraCare Life Sciences Inc., Solida Biotech GmbH, STEMCELL Technologies Inc., Thermo Fisher Scientific Inc. |
Driver: Rising awareness for cell-based vaccines
The prevalence of infectious diseases is rising globally. Cell culture technology can be used to prepare vaccines for various infectious diseases. The rising awareness for cell-based vaccines and their benefits is driving the growth of this market.
Restraints: High cost of research
Cell biology research consumes high quality reagents and equipment for providing accuracy in results. The regulatory approvals also insist the research to be done in highest quality to maintain standards. As a result, the research cost becomes very expensive which restraints the growth of this market.
Opportunity: Rising demand for 3D cell culture
The demand for 3D cell cultures is rising due to various advantages offered by 3D cell cultures as compared to 2D cell structures such as production of multi-dimensional cell cultures, better cell monitoring, greater stability and longer lifespan. Investors are also showing interest in this field which will significantly offer growth opportunities to this market.
Challenge: Generation of plastic waste
The cell culture relies on plastic consumables generating huge amount of plastic waste affecting the environment. The rising adoption of single-use bioprocessing systems is raising concerns related due to the disposal of solid waste materials. Recycling of such waste is not possible as it is composed of multiple plastic layers of polypropylene, nylon or polyethylene. The negative impact on the environment can be decreased in future with continuous research and development for eco-friendly equipment and techniques.
Cell Culture Market Segmentation:
By Product: Based on product, market has been segmented into Consumables (Sera, Media, and Reagents [Media (serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other media), Sera (fetal bovine sera (FBS), adult bovine sera (ABS), and other animal sera), Reagents (growth factors, supplements, buffers & chemicals, cell dissociation reagents, balanced salt solutions, attachment & matrix factors, antibiotics/antimycotics, contamination detection kits, cryoprotective agents, and other reagents)], Vessels [Roller/Roux Bottles, Cell Factory Systems/Cell Stacks, Multiwell Plates, Flasks, Petri Dishes], Accessories), Equipment (Supporting Equipment (filtration systems, cell counters, carbon dioxide incubators, centrifuges, autoclaves, microscopes, biosafety cabinets, and other supporting equipment such as pipetting aids, pipettes, cell inserts, cell scrapers, cell lifters, cell spreaders, pH meters, shakers, flow cytometers, and water baths), Bioreactors (conventional bioreactors, single-use bioreactors), Storage Equipment (Refrigerators & freezers, Cryostorage systems))
By Application:
Based on application, the market is segmented into Biopharmaceutical Production (Monoclonal antibodies, Vaccines production, Other therapeutic proteins), Diagnostics, Drug Screening & Development, Tissue Engineering & Regenerative Medicine (Cell and gene therapy, Other tissue engineering & regenerative medicine applications), Other Applications
By End User:
Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Research & Academic Institutes, Other End Users
Pharmaceutical & Biotechnological companies have the largest share of this market by end user due to highest consumption of cell culture equipment & consumables and expansion of manufacturing units to increase the production capacity.
By Region:
North America owns the largest share of this market owing to rising regulatory approvals for cell culture-based vaccines, rapidly evolving biotechnology and pharmaceutical sector, rising incidence of cancer, supportive government initiatives, technological advancements and rising investments in cell-based research and development.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary data
2.1.2. Primary data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impact of the Cell Culture Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL analysis
5.2.1. Political landscape
5.2.2. Economic landscape
5.2.3. Social landscape
5.2.4. Technological landscape
5.2.5. Environmental landscape
5.2.6. Legal landscape
5.3. PORTER’S five forces analysis
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of Buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat map analysis
6. Global Cell Culture Market, By Product, 2019-2030 (USD Million)
6.1. Consumables
6.1.1. Sera, Media, and Reagents
6.1.1.1. Media (serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other media)
6.1.1.2. Sera (fetal bovine sera (FBS), adult bovine sera (ABS), and other animal sera)
6.1.1.3. Reagents (growth factors, supplements, buffers & chemicals, cell dissociation reagents, balanced salt solutions, attachment & matrix factors, antibiotics/antimycotics, contamination detection kits, cryoprotective agents, and other reagents)
6.1.2. Vessels
6.1.2.1. Roller/Roux Bottles
6.1.2.2. Cell Factory Systems/Cell Stacks
6.1.2.3. Multiwell Plates
6.1.2.4. Flasks
6.1.2.5. Petri Dishes
6.1.3. Accessories
6.2. Equipment
6.2.1. Supporting Equipment (filtration systems, cell counters, carbon dioxide incubators, centrifuges, autoclaves, microscopes, biosafety cabinets, and other supporting equipment such as pipetting aids, pipettes, cell inserts, cell scrapers, cell lifters, cell spreaders, pH meters, shakers, flow cytometers, and water baths)
6.2.2. Bioreactors (conventional bioreactors, single-use bioreactors)
6.2.3. Storage Equipment (Refrigerators & freezers, Cryostorage systems)
7. Global Cell Culture Market, By Application, 2019-2030 (USD Million)
7.1. Biopharmaceutical Production
7.1.1. Monoclonal antibodies
7.1.2. Vaccines production
7.1.3. Other therapeutic proteins
7.2. Diagnostics
7.3. Drug Screening & Development
7.4. Tissue Engineering & Regenerative Medicine
7.4.1. Cell and gene therapy
7.4.2. Other tissue engineering & regenerative medicine applications
7.5. Other Applications
8. Global Cell Culture Market, By End User, 2019-2030 (USD Million)
8.1. Pharmaceutical & Biotechnology Companies
8.2. Hospitals & Diagnostic Laboratories
8.3. Research & Academic Institutes
8.4. Other End Users
9. Global Cell Culture Market, By Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. Company Profiles
10.1. Adolf Kühner AG
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Agilent Technologies, Inc.
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. ANGUS Chemical Company
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Becton, Dickinson and Company
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Biospherix Ltd.
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Caisson Laboratories Inc.
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Cellexus
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Corning Incorporated
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. Danaher Corporation
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Eppendorf AG
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. FUJIFILM Irvine Scientific, Inc.
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. Getinge AB
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. HiMedia Laboratories
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. InvivoGen
10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. Lonza Group AG
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. Meissner Filtration Products Inc.
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments
10.17. Merck KGaA
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments
10.18. Miltenyi Biotec
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments
10.19. Pan-Biotech GmbH
10.19.1. Company details
10.19.2. Financial outlook
10.19.3. Product summary
10.19.4. Recent developments
10.20. PromoCell GmbH
10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments
10.21. Sartorius AG
10.21.1. Company details
10.21.2. Financial outlook
10.21.3. Product summary
10.21.4. Recent developments
10.22. SeraCare Life Sciences Inc.
10.22.1. Company details
10.22.2. Financial outlook
10.22.3. Product summary
10.22.4. Recent developments
10.23. Solida Biotech GmbH
10.23.1. Company details
10.23.2. Financial outlook
10.23.3. Product summary
10.23.4. Recent developments
10.24. STEMCELL Technologies Inc.
10.24.1. Company details
10.24.2. Financial outlook
10.24.3. Product summary
10.24.4. Recent developments
10.25. Thermo Fisher Scientific Inc.
10.25.1. Company details
10.25.2. Financial outlook
10.25.3. Product summary
10.25.4. Recent developments